tert-butyl (4-((4-fluorobenzyl)oxy)phenethyl)carbamate | 788824-75-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl (4-((4-fluorobenzyl)oxy)phenethyl)carbamate
• 英文别名: tert-butyl N-[2-[4-[(4-fluorophenyl)methoxy]phenyl]ethyl]carbamate
• CAS: 788824-75-9
• 化学式: C₂₀H₂₄FNO₃
• 分子量: 345.414
• InChiKey: SZYRXDAQMMUPGV-UHFFFAOYSA-N

物化性质

• 沸点：
  481.4±35.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-((4-fluorobenzyl)oxy)phenethyl)carbamate 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙酸乙酯 、 乙腈 为溶剂， 反应 36.17h， 生成 2-((4-((4-fluorobenzyl)oxy)phenethyl)amino)propanamide
  参考文献：
  名称：

  治疗真菌感染的新型抗真菌药物的优化与评价

  摘要：

  由于真菌感染的发病率和死亡率增加以及严重的抗真菌耐药性的出现，迫切需要新的抗真菌药物。在这里，我们通过最低抑菌浓度测试在我们的内部库中筛选抗真菌活性，并衍生出两种具有中等抗真菌活性的命中化合物。通过取代各种芳环、烷基链和甲基，优化了命中化合物的抗真菌活性和类药特性。在优化的化合物中， 22h是最有前途的候选化合物，具有良好的类药特性，对多种真菌病原体表现出强效、快速的杀菌抗真菌作用，并与一些已知的抗真菌药物具有协同抗真菌活性。此外， 22h被进一步证实可以通过激活多个细胞壁完整性途径来扰乱真菌细胞壁的完整性。此外， 22h在皮下感染小鼠模型和离体人指甲感染模型中均发挥显着的抗真菌功效。

  DOI：

  10.1021/acs.jmedchem.1c01299
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 碳酸氢钠 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 tert-butyl (4-((4-fluorobenzyl)oxy)phenethyl)carbamate
  参考文献：
  名称：

  Trace Amine-Associated Receptor Agonists:  Synthesis and Evaluation of Thyronamines and Related Analogues

  摘要：

  We have previously shown that several thyronamines, decarboxylated and deiodinated metabolites of the thyroid hormone, potently activate an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale [Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S.; Lin, E. T.; Hatton, D.; Zucchi, R.; Grandy, D. K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10 (6), 638-642]. Herein, we report the synthesis of these thyronamines. Additionally, a large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction. Several derivatives were found to potently activate both rTAAR1 and mTAAR1 in vitro (compounds 77, 85, 91, and 92). When administered to mice at a 50 mg/kg dose, these derivatives all induced significant hypothermia within 60 min and exhibited a hypothermic induction profile analogous to 3-iodothyronamine (1, T(1)AM) except 91, which proved to be more efficacious. On the basis of this result, a dose-dependent profile for 91 was generated and an ED50 Of 30 mu mol/kg was calculated. Compound 91 proved to be more potent than T(1)AM for TAAR1 activation and exhibits increased potency and efficacy for hypothermia induction. These data further strengthen the pharmacological correlation linking TAAR1 activation by thyronamines and hypothermia induction in mice.

  DOI：

  10.1021/jm0505718

文献信息

• Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson’s disease therapy
  作者：Seul Ki Yeon、Ji Won Choi、Jong-Hyun Park、Ye Rim Lee、Hyeon Jeong Kim、Su Jeong Shin、Bo Ko Jang、Siwon Kim、Yong-Sun Bahn、Gyoonhee Han、Yong Sup Lee、Ae Nim Pae、Ki Duk Park

  DOI：10.1016/j.bmc.2017.11.036

  日期：2018.1

  inhibitory effect (hMAO-B IC50: 8.9 nM; >10,000-fold selectivity over MAO-A) as a competitive inhibitor. In addition, 12c showed greater MAO-B inhibitory activity and selectivity compared to well-known MAO-B inhibitors such as selegiline, safinamide and sembragiline. In the MPTP-induced mouse model of Parkinson’s disease (PD), 12c significantly protected the tyrosine hydroxylase (TH)-immunopositive DAergic

  苄氧基苯基部分是单胺氧化酶B（MAO-B），沙芬酰胺和司加吉林的高效，选择性和可逆抑制剂的常见结构。我们合成了在末端芳基单元上包含卤素取代基的4-（苄氧基）苯基和联苯-4-基衍生物。另外，我们修饰了胺基和联芳基连接单元之间的碳连接基。在合成的化合物中，12c作为竞争性抑制剂表现出最有效和选择性的MAO-B抑制作用（hMAO-B IC 50：8.9 nM；选择性比MAO-A高10,000倍）。另外，12c与著名的MAO-B抑制剂（例如司来吉兰，沙芬酰胺和sembragiline）相比，具有更高的MAO-B抑制活性和选择性。在MPTP诱发的帕金森氏病（PD）小鼠模型中，12c可显着保护酪氨酸羟化酶（TH）免疫阳性DAergic神经元，并减轻与PD相关的行为缺陷。这项研究表明，作为MAO-B抑制剂的特征结构可能为PD治疗药物的开发提供很好的见识。
• Thyronamine derivatives and analogs and methods of use thereof
  申请人：Scanlan S. Thomas

  公开号：US20050096485A1

  公开（公告）日：2005-05-05

  Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed

  本发明揭示了甲状腺胺衍生物和类似物，使用这些化合物的方法，以及含有它们的制药组合物。还揭示了制备这些化合物的方法。
• The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants
  作者：Jing Pu、Xiaoyang He、Wei Xu、Cong Wang、Qiaoshuai Lan、Chen Hua、Kai Wang、Lu Lu、Shibo Jiang

  DOI：10.3390/v14030489

  日期：——

  In recent years, infectious diseases caused by viral infections have seriously endangered human health, especially COVID-19, caused by SARS-CoV-2, which continues to spread worldwide. The development of broad-spectrum antiviral inhibitors is urgently needed. Here, we report a series of small-molecule compounds that proved effective against human coronaviruses (HCoV), such as SARS-CoV-2 and its variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), SARS-CoV, MERS-CoV, HCoV-OC43, and other viruses with class I viral fusion proteins, such as influenza virus, Ebola virus (EBOV), Nipah virus (NiV), and Lassa fever virus (LASV). They are also effective against class II enveloped viruses represented by ZIKV and class III enveloped viruses represented by vesicular stomatitis virus (VSV). Further studies have shown that these compounds may exert antiviral effects through a variety of mechanisms, including inhibiting the formation of the six-helix bundle, which is a typical feature of enveloped virus fusion with cell membranes, and/or targeting viral membrane to inactivate cell-free virions. These compounds are expected to become drug candidates against SARS-CoV-2 and other enveloped viruses.

  近年来，由病毒感染引起的传染病严重危及人类健康，特别是由SARS-CoV-2引起的COVID-19继续在全球范围内传播。迫切需要开发广谱抗病毒抑制剂。在这里，我们报告了一系列小分子化合物，证明其对人类冠状病毒（HCoV）有效，如SARS-CoV-2及其关注变异体（VOCs），包括Alpha（B.1.1.7），Beta（B.1.351），Gamma（P.1），Delta（B.1.617.2）和Omicron（B.1.1.529），SARS-CoV，MERS-CoV，HCoV-OC43以及其他具有I类病毒融合蛋白的病毒，如流感病毒，埃博拉病毒（EBOV），尼帕病毒（NiV）和拉沙热病毒（LASV）。它们还对ZIKV代表的II类包膜病毒和VSV代表的III类包膜病毒有效。进一步的研究表明，这些化合物可能通过多种机制发挥抗病毒作用，包括抑制六螺旋束的形成，这是包膜病毒与细胞膜融合的典型特征，和/或靶向病毒膜以失活游离病毒。这些化合物有望成为SARS-CoV-2和其他包膜病毒的药物候选物。
• THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF
  申请人：Scanlan Thomas S.

  公开号：US20090105347A1

  公开（公告）日：2009-04-23

  Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed

  本发明涉及甲状腺胺衍生物和类似物，使用这些化合物的方法以及包含它们的药物组合物。本发明还揭示了制备这些化合物的方法。
• US6979750B1
  申请人：——

  公开号：US6979750B1

  公开（公告）日：2005-12-27